Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

• Status: Recruiting
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Acetylcarnitine

Criteria

Inclusion Criteria:

• Age between 55 and 85 years old

• Patients with chronic cerebrovascular disease, who have modified Fazekas scale grade 2 ~ 3

• Patients wtih a diagnosis of MCI

• MOCA-K of 23 or less

• Patients who provided a signed written informed consent form

Exclusion Criteria:

• Patiens who are uneducated or illiterate

• Patiens previously treated with dementia

• Patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1

• Patients with cognitive impairment due to diseases other than cerebrovascular disease

• Patients with severe depression, schizophrenia, alcoholism, and drug dependence